506 related articles for article (PubMed ID: 21535940)
1. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells.
Kang SG; Jeun SS; Lim JY; Kim SM; Yang YS; Oh WI; Huh PW; Park CK
Childs Nerv Syst; 2008 Mar; 24(3):293-302. PubMed ID: 17968556
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
4. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby S; Eberstål S; Svensson A; Fritzell S; Bexell D; Siesjö P; Darabi A; Bengzon J
J Neuroimmunol; 2014 Sep; 274(1-2):240-3. PubMed ID: 25086876
[TBL] [Abstract][Full Text] [Related]
5. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
6. [IMMUNOGENICITY OF HUMAN UMBILICAL CORD BLOOD DERIVED MESENCHYMAL STEM CELLS AFTER OSTEOGENIC INDUCTION].
Yang D; Lin H; Liu G
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Jun; 28(6):752-7. PubMed ID: 26455231
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells.
Kim DS; Kim JH; Lee JK; Choi SJ; Kim JS; Jeun SS; Oh W; Yang YS; Chang JW
Stem Cells Dev; 2009 Apr; 18(3):511-9. PubMed ID: 18624673
[TBL] [Abstract][Full Text] [Related]
8. Umbilical cord blood stem cells: induction of differentiation into mesenchymal lineages by cell-cell contacts with various mesenchymal cells.
Park J; Setter V; Wixler V; Schneider H
Tissue Eng Part A; 2009 Feb; 15(2):397-406. PubMed ID: 18759667
[TBL] [Abstract][Full Text] [Related]
9. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells.
Ryu CH; Park SH; Park SA; Kim SM; Lim JY; Jeong CH; Yoon WS; Oh WI; Sung YC; Jeun SS
Hum Gene Ther; 2011 Jun; 22(6):733-43. PubMed ID: 21261460
[TBL] [Abstract][Full Text] [Related]
11. Umbilical cord blood-selected CD133(+) cells exhibit vasculogenic functionality in vitro and in vivo.
Finney MR; Fanning LR; Joseph ME; Goldberg JL; Greco NJ; Bhakta S; Winter DG; Forster M; Scheid PE; Sabe M; Pompili VJ; Laughlin MJ
Cytotherapy; 2010; 12(1):67-78. PubMed ID: 19878081
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats.
Xu G; Jiang XD; Xu Y; Zhang J; Huang FH; Chen ZZ; Zhou DX; Shang JH; Zou YX; Cai YQ; Kou SB; Chen YZ; Xu RX; Zeng YJ
Cell Biol Int; 2009 Apr; 33(4):466-74. PubMed ID: 18725309
[TBL] [Abstract][Full Text] [Related]
13. Umbilical cord blood-naive T cells but not adult blood-naive T cells require HLA class II on antigen-presenting cells for allo-immune activation.
Kloosterboer FM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
Hum Immunol; 2004 Apr; 65(4):328-39. PubMed ID: 15120187
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of umbilical cord-derived mesenchymal stem cells.
Shawki S; Gaafar T; Erfan H; El Khateeb E; El Sheikhah A; El Hawary R
Microbiol Immunol; 2015 Jun; 59(6):348-56. PubMed ID: 25869421
[TBL] [Abstract][Full Text] [Related]
16. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells.
Qin K; Tian G; Li P; Chen Q; Zhang R; Ke YQ; Xiao ZC; Jiang XD
J Neuroimmunol; 2012 Jan; 242(1-2):9-15. PubMed ID: 22123613
[TBL] [Abstract][Full Text] [Related]
17. Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells.
Hermankova B; Zajicova A; Javorkova E; Chudickova M; Trosan P; Hajkova M; Krulova M; Holan V
Immunobiology; 2016 Feb; 221(2):129-36. PubMed ID: 26416211
[TBL] [Abstract][Full Text] [Related]
18. Both interleukin-3 and interleukin-6 are necessary for better ex vivo expansion of CD133+ cells from umbilical cord blood.
Bordeaux-Rego P; Luzo A; Costa FF; Olalla Saad ST; Crosara-Alberto DP
Stem Cells Dev; 2010 Mar; 19(3):413-22. PubMed ID: 19656071
[TBL] [Abstract][Full Text] [Related]
19. Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1.
Jiao H; Guan F; Yang B; Li J; Shan H; Song L; Hu X; Du Y
Neurol India; 2011; 59(2):241-7. PubMed ID: 21483126
[TBL] [Abstract][Full Text] [Related]
20. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells.
Yu SP; Yang XJ; Zhang B; Ming HL; Chen C; Ren BC; Liu ZF; Liu B
Chin Med J (Engl); 2011 Sep; 124(17):2599-604. PubMed ID: 22040410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
